Animal models of amyotrophic lateral sclerosis

Amyotrophic Lateral Sclerosis

Volumn 1, Issue 5, 2000, Pages 301-312

  Doble, Adam ^a   Kennel, Philippe ^a  

^a SANOFI   (France)

Author keywords

amyotrophic lateral sclerosis; animal models; cytoskeleton; superoxide dismutase; transgenic mice

Indexed keywords

NEUROTOXIN; SUPEROXIDE DISMUTASE;

ANIMAL; DISEASE MODEL; DRUG EFFECT; GENETICS; HUMAN; MOTONEURON; MOTOR NEURON DISEASE; MOUSE; MOUSE MUTANT; PATHOLOGY; PATHOPHYSIOLOGY; REVIEW; TRANSGENIC MOUSE;

ANIMALS; DISEASE MODELS, ANIMAL; HUMANS; MICE; MICE, NEUROLOGIC MUTANTS; MICE, TRANSGENIC; MOTOR NEURON DISEASE; MOTOR NEURONS; NEUROTOXINS; SUPEROXIDE DISMUTASE;

EID: 0034572425     PISSN: 17482968     EISSN: 1471180X     Source Type: Journal    
DOI: 10.1080/146608200300079545     Document Type: Article

References (150)

1. Ludolph AC. Animal models for motor neuron diseases: research directions. Neurology 1996; 47 (Suppl 4): S228-S232. (Pubitemid 26422575)
2. Piero AP, Mitsumoto H. Animal models of ALS. Clin Neurosci 1996; 3: 375-385. (Pubitemid 27052172)
3. Price DL, Cleveland DW, Koliatsos VE Motor neuron disease and animal models. Neurobiol Dis 1994; 1: 3-11. (Pubitemid 124002846)
4. Sivellis Smitt P, De Jong JMBV. Animal models of amyotrophic lateral sclerosis and the spinal muscular atrophies. J Neurol Sci 1989; 91: 213-258.
5. Strong MJ, Garruto RM. Experimental paradigms of motor neuron degeneration. In: Woodruff ML, Nonneman AJ, eds. Toxin-induced models of neurological disorders. New York: Plenum Press, 1994: 39-88.
6. Okado N, Oppenheim RW. Cell death of motoneurons in the chick embryo spinal cord: the loss of motoneurons following removal of afferent inputs. J Neurosci 1984; 4: 1639-1652. (Pubitemid 14058680)
7. Oppenheim RW, Qin-Wei Y, Prevette D, Yan Q. Brain derived neurotrophic factor rescues developing avian motoneurons from cell death. Nature 1992; 360: 755-757. (Pubitemid 23012275)
8. Sendtner M, Hotmann B, Kolbeck R, et al. Brain-derived neurotrophic factor prevents the death of motoneurons in newborn rats after nerve section. Nature 1992; 360: 757-759. (Pubitemid 23012276)
9. Sendtner M, Kreutzberg GW, Thoenen H. Ciliary neurotrophic factor prevents the degeneration of motor neurons after axotomy. Nature 1990; 345: 440-441.
10. Yan Q, Elliott J, Snider WD. Brain-derived growth factor rescues spinal motoneurons from axotomy induced cell death. Nature 1992; 360: 753-755. (Pubitemid 23012274)
11. Engelhardt J, Joo F. An immune-mediated guinea pig model for lower motor neuron disease. J Neuroimmunol 1986; 12: 279-290. (Pubitemid 16013740)
12. Engelhardt JI, Appel SH, Killian JM. Experimental autoimmune motoneuron disease. Ann Neurol 1989; 26: 368-376. (Pubitemid 19230306)
13. Smith RG, Engelhardt JI, Tatji J, Appel SH. Experimental immune-mediated motor neuron disease: models for human ALS. Brain Res Bull 1993; 30: 373-380. (Pubitemid 23072746)
14. Chou SM, Hartman HA. Axonal lesions and waltzing syndrome after IDPN administration in rats. With a concept 'Axotasis'. Acta Neuropathol 1964; 3: 428-450.
15. Griffin JW, Hoffman PN, Clark AW, et al. Slow axonal transport of neurofilament proteins: impairment by β,β'-iminodiproprionitrile administration. Science 1978; 202: 633-635. (Pubitemid 9055619)
16. Clark AW, Grifin JW, Price DL. The axonal pathology in chronic IDPN intoxication. J Neuropathol Exp Neurol 1980; 39: 42-55. (Pubitemid 10148405)
17. Spencer PS, Nunn PB, Hugon J, et al. Guam amyotrophic lateral sclerosis-parkinsonism-dementia linked to a plant excitotoxin. Science 1987; 237: 517-522. (Pubitemid 17125919)
18. Nunn PB, Seelig M, Spencer PS. Stereospeciic acute neuronotoxicity of 'uncommon' plant amino acids linked to human motor system disease. Brain Res 1987; 410: 375-379. (Pubitemid 17083338)
19. Ross SM, Seelig M, Spencer PS. Speciic antagonism of excitotoxic action of 'uncommon' amino acids assayed in organotypic mouse cortical cultures. Brain Res 1987; 425: 120-127. (Pubitemid 17159375)
20. Weiss JH, Choi DW. β-N-methylamino-L-alanine neurotoxicity: requirement for bicarbonate as a cofactor. Science 1988; 241: 973-975.
21. Smith SE, Meldrum BS. Receptor site speciicity for the acute effects of beta-N-methylaminoalanine in mice. Eur J Pharmacol 1990; 187: 131-134. (Pubitemid 20323933)
22. Seawright AA, Brown AW, Nolan CC, Cavanagh JB. Selective degeneration of cerebellar cortical neurons caused by cycad neurotoxin, L- -methylaminoalanine (L-BMAA), in rats. Neuropathol Appl Neurobiol 1990; 16: 153-169. (Pubitemid 20146624)
23. Duncan MW, Steele JC, Kopin IJ, Markey SP. 2-Amino3-(methylamino)- propionic acid (BMAA) in cycad flour, an unlikely cause of amyotrophic lateral sclerosis and parkinsonism-dementia of Guam. Neurology 1990; 40: 767-772. (Pubitemid 20159611)
24. Hirono I. Carcinogenicity and neurotoxicity of cycasin with special reference to species differences. Fed Proc 1972; 31: 1493-1497.
25. Jones MM, Yang M, Mickelsen O. Effects of methylazoxymethanol glucoside and methylazoxymethanol acetate on the cerebellum of the postnatal Swiss albino mouse. Fed Proc 1972; 31: 1508-1511.
26. Spencer PS, Ludolph A, Dwivedi MP, et al. Lathyrism: evidence for role of the neuroexcitatory amino acid BOAA. Lancet 1986; ii: 1066-1070.
27. Pearson S, Nunn PB. The neurolathyrogen, β-N-oxalyl- L-α,β-diaminopropionic acid, is a potent agonist at 'glutamate preferring' receptors in frog spinal cord. Brain Res 1981; 206: 178-182. (Pubitemid 11143586)
28. Rao SLN, Sarma PS, Mani KS, et al. Experimental neurolathyrism in monkeys. Nature 1967; 214: 610-611.
29. Hugon J, Ludolph A, Roy DN, et al. Studies on the aetiology and pathogenesis of motor neuron diseases. II. Clinical and electrophysiologic features of pyramidal dysfunction in macaques fed Lathyrus sativus and IDPN. Neurology 1988; 38: 435-442. (Pubitemid 18083685)
30. Pisharodi M, Nauta HJ. An animal model for neuronspecific cord lesions by the microinjection of N-methylaspartate, kainic acid and quisqualic acid. Appl Neurophysiol 1985; 48: 226-233. (Pubitemid 16064598)
31. Hugon J, Vallat JM, Spencer PS, et al. Kainic acid induces early and delayed degenerative neuronal changes in rat spinal cord. Neurosci Lett 1989; 104: 258-262. (Pubitemid 19231142)
32. Hugon J, Vallat JM. Abnormal distribution of phosphorylated neuroilaments in neuronal degeneration induced by kainic acid. Neurosci Lett 1990; 119: 45-48. (Pubitemid 20349723)
33. Ikonomidou C, Qin Y, Labruyere J, Olney JW. Motor neuron degeneration induced by excitotoxin agonists has features in common with those seen in the SOD1 transgenic mouse model of amyotrophic lateral sclerosis. J Neuropathol Exp Neurol 1996; 55: 211-224. (Pubitemid 26069299)
34. DeBoni U, Otvos A, Scott JW, Crapper DR. Neurofibrillary degeneration induced by systemic aluminium. Acta Neuropathol 1976; 35: 285-294.
35. Wisniewski HM, Sturman JA, Shek JW. Chronic model of neuroibrillary changes induced in mature rabbits by metallic aluminium. Neurobiol Aging 1982; 3: 11-22. (Pubitemid 12066361)
36. Garruto RM, Shankar SK, Yanagihara R, et al. Low-calcium, high-aluminium diet-induced motor neuron pathology in cynomolgus monkeys. Acta Neuropathol (Berlin) 1989; 78: 210-219. (Pubitemid 19160926)
37. Strong MJ, Garruto RM. Chronic aluminium-induced motor neuron degeneration: clinical, neuropathological and molecular biological aspects. Can J Neurol Sci 1991; 18: 428-431.
38. Strong MJ, Wolff AV, Wakayama I, Garruto RM. Aluminium-induced chronic myelopathy in rabbits. Neurotoxicology 1991; 12: 9-22.
39. Troncoso JC, Price DL, Grifin JW, Parhad IM. Neuroibrillary axonal pathology in aluminium intoxication. Ann Neurol 1982; 12: 278-283. (Pubitemid 12053036)
40. Messer A, Flaherty L. Autosomal dominant inheritance in a late-onset motor neuron disease in the mouse. J Neurogenet 1986; 3: 345-355. (Pubitemid 17186032)
41. Messer A, Plummer J, Maskin P, et al. Mapping of the lateonset motor neuron degeneration (Mnd) gene. Genomics 1992; 18: 797-802.
42. Messer A, Strominger NL, Mazurkiewicz JE. Histopathology of the late-onset motor neuron degeneration (Mnd) mutant in the mouse. J Neurogenet 1987; 4: 201-213. (Pubitemid 17121344)
43. Faust JR, Rodman JS, Daniel PF, et al. Two related proteolipids and dolichol-linked oligosaccharides accumulate in motor neuron degeneration mice (mnd/mnd), a model for neuronal ceroid lipofuscinosis. J Biol Chem 1994; 269: 10150-10155. (Pubitemid 24196635)
44. Pardo CA, Rabin BA, Palmer DN, et al. Accumulation of the adenosine triphosphate synthase subunit c in the mnd mutant mouse. A model for neuronal ceroid lipofuscinosis. Am J Pathol 1993; 144: 829-835. (Pubitemid 24172071)
45. Callahan LM, Wylen EL, Messer A, Mazurkiewicz JE. Neuroilament distribution is altered in the Mnd (motor neuron degeneration) mouse. J Neuropathol Exp Neurol 1991; 50: 491-504.
46. Mazurkiewicz JE. Ubiquitin deposits are present in spinal motoneurons in all stages of the disease in the motor neuron degeneration (mnd) mutant of the mouse. Neuro Sci Lett 1991; 128: 182-186.
47. Bronson RT, Lake BD, Cook S, et al. Motor neuron degeneration of mice is a model of neuronal ceroid lipofuscinosis (Batten's Disease). Ann Neurol 1993; 33: 381-385. (Pubitemid 23103970)
48. Battaglioli G, Martin DL, Plummer J, Messer A. Synaptosomal glutamate uptake declines progressively in the spinal cord of a mutant mouse with motor neuron disease. J Neurochem 1993; 60: 1567-1569. (Pubitemid 23088337)
49. Boyce S, Webb JK, Carlson E, et al. Onset and progression of motor deicits in motor neuron degeneration (Mnd) mice are unaltered by the glycine/NMDA receptor antagonist L-701,324 or the MAO-B inhibitor R(-)deprenyl. Exp Neurol 1999; 155: 49-58.
50. Winter CG, Saotome Y, Saotome I, Hirsh D. CNTF overproduction hastens onset of symptoms in motor neuron degeneration (mnd) mice. J Neurobiol 1996; 31: 370-378. (Pubitemid 26362232)
51. Kaupmann K, Simon-Chazottes D, Guénet JL, Jockush H. Wobbler, a mutation affecting motoneuron survival and gonadal function in the mouse, maps to proximal chromosome 11. Genomics 1992; 13: 39-43.
52. Duchen LW, Strich SJ. An hereditary motor neuron disease with progressive denervation of muscle in the mouse: the mutant 'wobbler'. J Neurol Neurosurg Psychiat 1968; 31: 535-542.
53. Bird MT, Shuttleworth E, Doestner A, Reinglass J. The wobbler mouse mutant: an animal model of hereditary motor system disease. Acta Neuropathol (Berlin) 1971; 92: 789-804.
54. Mitsumoto H, Bradley WG. Murine motor neuron disease (the Wobbler mouse): degeneration and regeneration of the lower motor neuron. Brain 1982; 105: 811-834. (Pubitemid 13241013)
55. LaVail JH, Koo EH, Dekker NP. Motoneuron loss in the abducens nucleus of wobbler mice. Brain Res 1988; 463: 78-89.
56. Ma W, Vacca-Galloway LL. Reduced branching and length of dendrites detected in cervical spinal motoneurons of the wobbler mouse, a model of inherited motoneuron disease. J Comp Neurol 1991; 311: 210-222.
57. Hantaz-Ambroise D, Blondet D, Murawsky M, et al. Abnormal astrocyte differentiation and defective cellular interactions in wobbler mouse spinal cord. J Neurocytol 1994; 23: 179-192. (Pubitemid 24105844)
58. Murakami T, Mastaglia FL, Bradley WG. Reduced protein synthesis in spinal anterior horn neurons in Wobbler mouse mutant. Muscle Nerve 1981; 4: 407-412.
59. Pioro EP, Wang Y, Moore JK, et al. Neuronal pathology in the wobbler mouse brain revealed by in vivo proton magnetic resonance spectroscopy and immunocytochemistry. Neuro Report 1998; 9: 3041-3046. (Pubitemid 28555643)
60. Krieger C, Perry TL, Hansen S, Mitsumoto H. The wobbler mouse: amino acid contents in brain and spinal cord. Brain Res 1991; 551: 142-144.
61. Tomiyama M, Kannari K, Nunomura J, et al. Quantitative autoradiographic distribution of glutamate receptors in the cervical segment of the spinal cord of the wobbler mouse. Brain Res 1994; 650: 353-357. (Pubitemid 24207086)
62. Leestma JE, Sepsenwol S. Sperm tail axoneme alterations in the Wobbler mouse. J Reprod Fertil 1980; 58: 267-270.
63. Hantai D, Akkaboune M, Lagord C, et al. Beneicial effects of insulin-like growth factor-I in wobbler mouse motoneurone disease. J Neurol Sci 1995; 129 (Suppl): 122-126.
64. Mitsumoto H, Ikeda K, Klinkosz B, et al. Arrest of motor neuron disease in wobbler mice cotreated with CNTF and BDNF. Science 1994; 265: 1107-1110. (Pubitemid 24293081)
65. Henderson JT, Javaheri M, Kopko S, Roder JC. Reduction of lower motor neuron degeneration in wobbler mice by N-acetyl-L-cysteine. J Neurosci 1996; 16: 7574-7582. (Pubitemid 26389697)
66. Krieger C, Perry TK, Hansen S, et al. Excitatory amino acid receptor antagonist in murine motoneuron disease (the wobbler mouse). Can J Neurol Sci 1992; 19: 462-465.
67. Schultz LD, Sweet HO, Davisson MT, Coman DR. ''Wasted'', a new mutant of the mouse with abnormalities characteristic of ataxia telangiectasia. Nature 1982; 297: 402-404.
68. Chambers DM, Peters J, Abbott CM. The lethal mutation of the mouse wasted (wst) is a deletion that abolishes expression of a tissue-speciic isoform of translation elongation factor 1α, encoded by the Eef1a2 gene. Proc Natl Acad Sci USA 1998; 95: 4463-4468.
69. Lutsep HL, Rodriguez M. Ultrastructural, morphometric and immunocytochemical study of anterior horn cells in mice with 'wasted' mutation. J Neuropathol Exp Neurol 1989; 48: 519-533. (Pubitemid 19220608)
70. Kaiserlian D, Savino W, Uriel J, et al. The wasted mutant mouse. II. Immunological abnormalities in a mouse described as a model of ataxia-telangiectasia. Clin Exp Immunol 1986; 63: 562-569. (Pubitemid 16128994)
71. Libertin CR, Ling-Indeck L, Padilla M, Woloschak GE. Cytokine and T-cell subset abnormalities in immunodeicient wasted mice. Mol Immunol 1994; 31: 753-759. (Pubitemid 24244307)
72. Brunialti ALB, Poirier C, Schmalbruch H, Guénet JL. The mouse mutation progressive motor neuropathy maps to chromosome 13. Genomics 1995; 29: 131-135.
73. Schmalbruch H, Skovgaad Jensen HJ, Bjerg B, et al. A new mouse mutant with progressive motor neuropathy. J Neuropathol Exp Neurol 1991; 50: 192-204.
74. Kennel PF, Fonteneau P, Martin E, et al. Electromyographical and motor performance studies in the pmn mouse model of neurodegenerative disease. Neurobiol Dis 1996; 3: 137-147. (Pubitemid 26275343)
75. Sendtner M, Schmalbruch H, Stöckli KA, et al. Ciliary neurotrophic factor prevents degeneration of motor neurons in mouse mutant progressive motor neuronopathy. Nature 1992; 358: 502-504.
76. Haase G, Kennel P, Pettmann B, et al. Gene therapy of murine motor neuron disease using adenoviral vectors for neurotrophic factors. Nature Med 1998; 3: 429-436.
77. Sagot T, Tan SA, Hammang JP, et al. GDNF slows loss of motoneurones but not axonal degeneration or premature death of pmn mice. J Neurosci 1996; 16: 2335-2341. (Pubitemid 26157555)
78. Kennel P, Revah F, Bohme G, et al. Riluzole prolongs survival and delays muscle strength deterioration in mice with progressive motor neuronopathy (pmn). J Neurol Sci 2000; 180: 66-67.
79. Duong F, Fournier J, Keane PE, et al. The effect of the nonpeptide neurotrophic compound SR 57746A on the progression of the disease state of the pmn mouse. Br J Pharmacol 1998; 124: 811-817. (Pubitemid 28276820)
80. Larrodé Pellicer P, Hernando de la Bárcena I. ELA experimental. Modelos experimentales. In: Mora Pardina JS, ed. Esclerosis lateral amiotrófica. Una enfermedad tratable. Barcelona: Prous Science, 1999: 333-351.
81. Ikeda K, Kinoshita M, Tagaya N, et al. Coadministration of interleukin-6 (IL-6) and soluble IL-6 receptor delays progression of wobbler mouse motor neuron disease. Brain Res 1996; 726: 91-97. (Pubitemid 26292234)
82. Ikeda K, Iwasaki Y, Tagaya N, et al. Neuroprotective effect of basic ibroblast growth factor on wobbler mouse motor neuron disease. Neurol Res 1995; 17: 455-448.
83. Ikeda K, Iwasaki Y, Kinoshita M. Neuronal nitric oxide synthase inhibitor, 7-nitroxyindole, delays motor dysfunction and spinal motoneuron degeneration in the wobbler mouse. J Neurol Sci 1998; 160: 9-15. (Pubitemid 28473879)
84. Abe K, Morita S, Kikuchi T, Itoyama Y. Protective effect of a novel free radical scavenger, OPC-14117, on wobbler mouse motor neuron disease. J Neurol Sci 1997; 48: 63-70. (Pubitemid 27147892)
85. Ikeda K, Iwasaki Y, Kinoshita M. JTP-2942, a novel thyrotropin-releasing hormone analogue, protects against spinal motor neuron degeneration in the wobbler mouse. Neurosci Lett 1998; 250: 9-12. (Pubitemid 28341764)
86. Gonzalez-Deniselle MC, Gonzalez SL, Lima AE, et al. The 21-aminosteroid U-74389F attenuates hyperexpression of GAP-43 and NADPH-diaphorase in the spinal cord of wobbler mouse, a model for amyotrophic lateral sclerosis. Neurochem Res 1999; 24: 1-8. (Pubitemid 29067769)
87. Sagot Y, Dubois-Dauphin M, Tan SA, et al. Bcl-2 overexpression prevents motoneuron cell body loss but not axonal degeneration in a mouse model of a neurodegenerative disease. J Neurosci 1995; 15: 7727-7733.
88. Lorentz MD, Cork LC, Grifin JW, et al. Hereditary spinal muscular atrophy in Brittany spaniels: clinical manifestations. J Am Vet Med Assoc 1979; 175: 833-839. (Pubitemid 10190150)
89. Cork LC, Grifin JW, Munnell JF, et al. Hereditary canine spinal muscular atrophy. J Neuropathol Exp Neurol 1979; 38: 209-221. (Pubitemid 9179808)
90. Grifin JW, Cork LC, Adams RJ, Price DL. Axonal transport in hereditary canine spinal muscular atrophy. J Neuropathol Exp Neurol 1982; 41: 370.
91. Cork LC, Grifin JW, Choy C, et al. Pathology of motor neurons in accelerated hereditary canine spinal muscular atrophy. Lab Invest 1982; 46: 88-99.
92. Sack GH, Cork LC, Morris JM, et al. Autosomal dominant inheritance of hereditary canine spinal muscular atrophy. Ann Neurol 1984; 15: 369-373. (Pubitemid 14139473)
93. Cork LC, Griffin JW, Price DL, Sack GH. Hereditary canine spinal muscular atrophy: canine motor neuron disease. Can J Vet Res 1990; 54: 77-82.
94. Cork LC. Hereditary canine spinal muscular atrophy: an animal model of neuron disease. Can J Neurol Sci 1991; 18: 432-434.
95. Cork LC, Struble RG, Gold BG, et al. Changes in size of motor axons in hereditary canine spinal muscular atrophy. Lab Invest 1989; 61: 333-342. (Pubitemid 19249647)
96. Cummings JF, DeLahunta A, George C, et al. Equine motor neuron disease; a preliminary report. Cornell Vet 1990; 80: 357-379.
97. Cummings JF, DeLahunta A, Summers BA, et al. Eosinophilic cytoplasmic inclusions in sporadic equine motor neuron disease: an electron microscopic study. Acta Neuropathol 1993; 85: 291-297. (Pubitemid 23081178)
98. Mohammed HO, Cummings JF, Divers TJ, et al. Risk factors associated with equine motor neuron disease: a possible model for human MND. Neurology 1993; 43: 966-971. (Pubitemid 23150570)
99. Brown JH. Amyotrophic lateral sclerosis: recent insights from genetics and transgenic mice. Cell 1995; 80: 687-692.
100. Bruijn LI, Cleveland DW. Mechanisms of selective motor neuron death in ALS: insights from transgenic mouse models of motor neuron disease. Neuropathol Appl Neurobiol 1996; 22: 373-387. (Pubitemid 26355740)
101. Cleveland DW, Bruijn LI, Wong PC, et al. Mechanisms of selective motor neuron death in transgenic mouse models of motor neuron disease. Neurology 1996; 47 (Suppl 2): S54-S62. (Pubitemid 26361996)
102. Lee MK, Borchelt DR, Wong PC, et al. Transgenic models of neurodegenerative diseases. Curr Opin Neurobiol 1996; 6: 651-660. (Pubitemid 26387721)
103. Borchelt DR, Wong PC, Sisodia SS, Price DL. Transgenic mouse models of Alzheimer's disease and amyotrophic lateral sclerosis. Brain Pathol 1998; 8: 735-757. (Pubitemid 28460931)
104. Gurney ME, Pu H, Chiu AY, et al. Motor neuron degeneration in mice that express a human Cu, Zn superoxide dismutase mutation. Science 1994; 264: 1772-1775. (Pubitemid 24227760)
105. Wong PC, Pardo CA, Borchelt DR, et al. An adverse property of a familial ALS-linked SOD1 mutation causes motor neuron disease characterized by vacuolar degeneration of mitochondria. Neuron 1995; 14: 1105-1106.
106. Ripps ME, Huntley GW, Hof PR, et al. Transgenic mice expressing an altered murine superoxide dismutase gene provide an animal model of amyotrophic lateral sclerosis. Proc Natl Acad Sci USA 1995; 92: 659-693.
107. Bruijn LI, Becher MW, Lee MK, et al. ALS-linked SOD1 mutant G85R mediated damage to astrocytes and promotes rapidly progressive disease with SOD1-containing inclusions. Neuron 1997; 18: 327-388.
108. Reaume AG, Elliott JL, Hoffman EK, et al. Motor neurons in Cu/Zn superoxide dismutase-deicient mice develop normally but exhibit enhanced cell death after axonal injury. Nat Genet 1996; 13: 43-47. (Pubitemid 26139292)
109. Barnéoud P, Lolivier J, Sanger DJ, et al. Quantitative motor assessment in FALS mice: a longitudinal study. Neuro Report 1997; 8: 2861-2865. (Pubitemid 27394808)
110. Chiu AY, Zhai P, Dal Canto MC, et al. Age-dependent penetrance of disease in a transgenic mouse model of familial amyotrophic lateral sclerosis. Mol Cell Neurosci 1995; 6: 349-362.
111. Gurney ME. The use of transgenic mouse models of amyotrophic lateral sclerosis in preclinical drug studies. J Neurol Sci 1997; 152 (Suppl 1): S67-S73. (Pubitemid 27505293)
112. Kennel PF, Finiels F, Revah F, Mallet J. Neuromuscular function impairment is not caused by motor neurone loss in FALS mice: an electromyographic study. Neuro Report 1996; 7: 1427-1431. (Pubitemid 26281007)
113. Kong J, Xu Z. Massive mitochondrial degeneration in motor neurons triggers the onset of amyotrophic lateral sclerosis in mice expressing a mutant SOD1. J Neurosci 1998; 18: 3241-3250. (Pubitemid 28186017)
114. Del Canto MC, Gurney ME. The development of central nervous system pathology in a murine transgenic model of human amyotrophic lateral sclerosis. Am J Pathol 1994; 145: 1271-1279. (Pubitemid 24378480)
115. Tu PH, Raju P, Robinson KA, et al. Transgenic mice carrying a human mutant superoxide dismutase transgene develop neuronal cytoskeletal pathology resembling human amyotrophic lateral sclerosis lesions. Proc Natl Acad Sci USA 1996; 93: 3155-3160. (Pubitemid 26114380)
116. Ferrante RJ, Shinobu LA, Schulz JB. Increased 3-nitrotyrosine and oxidative damage in mice with a human copper/zinc superoxide dismutase mutation. Ann Neurol 1997; 42: 326-334. (Pubitemid 27391116)
117. Bruijn LI, Beal MF, Becher MW, et al. Elevated free nitrotyrosine levels, but not protein-bound nitrotyrosine or hydroxyl radicals, throughout amyotrophic lateral sclerosis (ALS)-like disease implicate tyrosine nitration as an aberrant in vivo property of one familial ALS-linked superoxide dismutase 1 mutant. Proc Natl Acad Sci USA 1997; 94: 7606-7611.
118. Bogdanov MB, Ramos LE, Xu X, Beal MF. Elevated 'hydroxyl radical' generation in vivo in an animal model of amyotrophic lateral sclerosis. J Neurochem 1998; 71: 1321-1324. (Pubitemid 28390288)
119. Canton T, Pratt J, Stutzmann JM, et al. Glutamate uptake is decreased tardively in the spinal cord of FALS mice. NeuroReport 1998; 30: 775-778. (Pubitemid 28179273)
120. Collard JF, Côté F, Julien JP. Defective axonal transport in a transgenic mouse model of amyotrophic lateral sclerosis. Nature 1995; 375: 61-64.
121. Zhang B, Ti PH, Abtahian F, et al. Neuroilaments and orthograde transport are reduced in ventral root axons of transgenic mice that express human SOD1 with a G93A mutation. J Cell Biol 1997; 5: 1307-1315. (Pubitemid 27523216)
122. Hall ED, Oostveen JA, Gurney ME. Relationship of microglial and astrocytic activation to disease onset and progression in a transgenic model of familial ALS. Glia 1998; 23: 249-256. (Pubitemid 28259722)
123. Kostic V, Gurney ME, Deng HX, et al. Midbrain dopaminergic neuronal degeneration in a transgenic mouse model of familial amyotrophic lateral sclerosis. Ann Neurol 1997; 41: 497-504. (Pubitemid 27169189)
124. Pasinelli P, Borchelt DR, Houseweart MK, et al. Caspase-1 is activated in neural cells and tissue with amyotrophic lateral sclerosis-associated mutations in copper-zinc superoxide dismutase. Proc Natl Acad Sci USA 1998; 26: 15763-15768. (Pubitemid 29018774)
125. Ghadge GD, Lee JP, Bindokas VP, et al. Mutant superoxide dismutase-1-linked familial amyotrophic lateral sclerosis: molecular mechanisms of neuronal death and protection. J Neurosci 1997; 17: 8756-8766. (Pubitemid 27481742)
126. Rabizadeh S, Gralla EB, Borchelt DR, et al. Mutations associated with amyotrophic lateral sclerosis convert superoxide dismutase from an antiapoptotic gene to a proapoptotic gene: studies in yeast and neural cells. Proc Natl Acad Sci USA 1995; 92: 3024-3028.
127. Durham HD, Roy J, Dong L, Figlewicz DA. Aggregation of mutant Cu/Zn superoxide dismutase proteins in a culture model of ALS. J Neuropathol Exp Neurol 1997; 56: 523-530. (Pubitemid 27463093)
128. Gurney ME, Cutting FB, Zhai P, et al. Beneit of vitamin E, riluzole and gabapentin in a transgenic model of familial amyotrophic lateral sclerosis. Ann Neurol 1996; 39: 147-157. (Pubitemid 26071564)
129. Barnéoud P, Curet O. Beneicial effects of lysine acetylsalicylate, a soluble salt of aspirin, on motor performance in a transgenic model of amyotrophic lateral sclerosis. Exp Neurol 1999; 155: 243-251. (Pubitemid 29124717)
130. Klivenyi P, Ferrante RJ, Matthews RT, et al. Neuroprotective effects of creatine in a transgenic animal model of amy- otrophic lateral sclerosis. Nature Med 1999; 5: 347-350. (Pubitemid 29124375)
131. Gurney ME, Fleck TJ, Himes CS, Hall ED. Riluzole preserves motor function in a transgenic model of familial amyotrophic lateral sclerosis. Neurology 1998; 50: 62-66. (Pubitemid 28106020)
132. Facchinetti F, Sasaki M, Cutting FB, et al. Lack of involvement of neuronal nitric oxide synthase in the pathogenesis of a transgenic mouse model of familial amyotrophic lateral sclerosis. Neuroscience 1999; 90: 1483-1492. (Pubitemid 29170162)
133. Mohajeri MH, Figlewicz DA, Bohn MC. Intramuscular grafts of myoblasts genetically modiied to secrete Glial Cell-LineDerived Neurotrophic factor prevent motoneuron loss and disease progression in a mouse model of familial amyotrophic lateral sclerosis. Hum Gene Ther 1999; 10: 1853-1866. (Pubitemid 29357691)
134. Hottinger AF, Fine EG, Gurney ME, et al. The copper chelator D-penicillamine delays onset of disease and extends survival in a transgenic mouse model of familial amyotrophic lateral sclerosis. Eur J Neurosci 1997; 9: 1548-1551. (Pubitemid 27303257)
135. Nagano S, Ogawa Y, Yanagihara T, Sakoda S. Beneit of a combined treatment with trientine and ascorbate in familial amyotrophic lateral sclerosis model mice. Neurosci Lett 1999; 265: 159-162. (Pubitemid 29207390)
136. Dugan LL, Turetsky DM, Du C, et al. Carboxyfullerenes as neuroprotective agents. Proc Natl Acad Sci USA 1997; 94: 9434-9439. (Pubitemid 27357847)
137. Kostic V, Jackson-Lewis V, de Bilbao F, et al. Bcl-2 prolongs life in a transgenic mouse model of familial amyotrophic lateral sclerosis. Science 1997; 277: 559-562. (Pubitemid 27369003)
138. Frielander RM, Brown RH, Gagliardini V, et al. Inhibition of ICE slows ALS in mice. Nature 1997; 388: 31. (Pubitemid 27283876)
139. Li M, Ona VO, Guegan C, et al. Functional role of caspase-1 and caspase-3 in an ALS transgenic mouse model. Science 2000; 288: 335-339. (Pubitemid 30226195)
140. Julien JP. Neuroilament functions in health and disease. Curr Opin Neurobiol 1999; 9: 554-560.
141. Leigh PN, Swash M. Cytoskeletal pathology in motor neuron diseases. Adv Neurol 1991; 56: 115-124.
142. Figlewicz DA, Krizus A, Martinoli MG, et al. Variants of the heavy neuroilament subunit are associated with the development of amyotrophic lateral sclerosis. Hum Mol Genet 1994; 3: 1757-1761. (Pubitemid 24310467)
143. Al-Chalabi A, Andersen PM, Nilsson P, et al. Deletions of the heavy neuroilament subunit tail in amyotrophic lateral sclerosis. Hum Mol Genet 1999; 8: 157-164. (Pubitemid 29054257)
144. Beaulieu JM, Nguyen MD, Julien JP. Late onset death of motor neurons in mice over-expressing wild-type peripherin. J Cell Biol 1999; 147: 531-544. (Pubitemid 29523460)
145. Cote F, Collard JF, Julien JP. Progressive neuronopathy in transgenic mice expressing the human neuroilament heavy gene: a mouse model of amyotrophic lateral sclerosis. Cell 1993; 73: 35-46. (Pubitemid 23115447)
146. Meier J, Couillard-Després S, Jacomy H, et al. Extra neuroilament NF-L subunits rescue motor neuron disease caused by overexpression of the human NF-H gene in mice. J Neuropathol Exp Neurol 1999; 58: 1099-1110. (Pubitemid 29468271)
147. Couillard-Després S. Zhu Q, Wong PC, et al. Protective effect of neurofilament heavy gene overexpression in motor neuron disease induced by mutant superoxide dismutase. Proc Natl Acad Sci USA 1998; 16: 9626-9630. (Pubitemid 28506282)
148. Xu Z, Cork LC, Grifin JW, et al. Increased expression of neuroilament subunit NF-L produces morphological alterations that resemble the pathology of human motor neuron disease. Cell 1993; 73: 23-33. (Pubitemid 23115446)
149. Williamson TI, Bruijn LI, Zhu Q, et al. Absence of neuroilaments reduces the selective vulnerability of motor neurons and slows disease caused by a familial amyotrophic lateral sclerosis-linked superoxide dismutase 1 mutant. Proc Natl Acad Sci USA 1998; 16: 9631-9636.
150. Lee MK, Cleveland DW. A mutant neuroilament subunit causes massive, selective motor neuron death: implications for the pathogenesis of human motor neuron disease. Neuron 1994; 13: 975-988. (Pubitemid 24347310)